Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raskin, N. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raskin, N. H.
NEUROLOGY 1986;36:995
© 1986 American Academy of Neurology

Repetitive intravenous dihydroergotamine as therapy for intractable migraine

Neil H. Raskin, MD

University of California, San Francisco, School of Medicine, San Francisco, CA.

For patients with chronic intractable headache, we compared a new treatment and a traditional one. Fifty-five patients (36 dependent on ergotamine, analgesics, diazepam, or corticosteroids) were given IV dihydroergotamine (DHE) and metoclopramide every 8 hours. Fifty-four age- and sex-matched patients (38 drug-dependent) were given diazepam intravenously every 8 hours. Forty-nine of the 55 DHE-treated patients became headache-free within 48 hours, and 39 of them sustained benefits in a mean follow-up of 16 months. In contrast, 7 diazepam-treated patients became free of headache within 3 to 6 days, and 31 had improved somewhat in 10 days. Repetitive IV DHE helps to terminate cycles of intractable migraine.

Address correspondence and reprint requests to Dr. Raskin, University of California, San Francisco, School of Medicine, San Francisco, CA 94143.

Accepted for publication November 6, 1985.




This article has been cited by other articles:


Home page
Journal of Pharmacy PracticeHome page
T. Tucker
A Practical Approach to Headache Treatment
Journal of Pharmacy Practice, April 1, 2007; 20(2): 123 - 136.
[Abstract] [PDF]


Home page
JAOA: Journal of the American Osteopathic AssociationHome page
A. D. Hershey and P. K. Winner
Pediatric Migraine: Recognition and Treatment
J Am Osteopath Assoc, April 1, 2005; 105(4_suppl): 2S - 8S.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
P. J Goadsby and C. Boes
CHRONIC DAILY HEADACHE
J. Neurol. Neurosurg. Psychiatry, June 1, 2002; 72(90002): ii2 - 5.
[Full Text]


Home page
NeurologyHome page
Z. Katsarava, G. Fritsche, M. Muessig, H.C. Diener, and V. Limmroth
Clinical features of withdrawal headache following overuse of triptans and other headache drugs
Neurology, November 13, 2001; 57(9): 1694 - 1698.
[Abstract] [Full Text] [PDF]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
P. J GOADSBY
A triptan too far?
J. Neurol. Neurosurg. Psychiatry, February 1, 1998; 64(2): 143 - 147.
[Full Text] [PDF]


Home page
NEJMHome page
K.M.A. Welch
Drug Therapy of Migraine
N. Engl. J. Med., November 11, 1993; 329(20): 1476 - 1483.
[Full Text]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1986 by AAN Enterprises, Inc.